Breaking News
Start for Free 0
🥇 First rule of investing? Know when to save! Up to 55% off Investing Pro before BLACK FRIDAY
CLAIM SALE
Close

Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
15.68 +0.08    +0.51%
11/11 - Closed. Currency in CNY
Type:  Equity
Market:  China
ISIN:  CNE000000735 
  • Volume: 22,288,722
  • Bid/Ask: 15.68 / 15.68
  • Day's Range: 15.44 - 15.93
Golden Horse A 15.68 +0.08 +0.51%

SZ:000766 Financials

 
Gain a comprehensive overview of Golden Horse A financials. Assess key figures from the balance sheet and income statement. Explore essential metrics such as total assets, total liabilities, equity, revenue, and net income to understand the company’s overall financial performance.

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd reported earnings results for the nine months ended September 30, 2024. For the nine months, the company reported sales was CNY 968.59 million compared to CNY 1,044.24 million a year ago. Net income was CNY 23.92 million compared to CNY 15.55 million a year ago. Basic earnings per share from continuing operations was CNY 0.0248 compared to CNY 0.0161 a year ago. Diluted earnings per share from continuing operations was CNY 0.0248 compared to CNY 0.0161 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

000766 Income Statement

Gross margin TTM -
Operating margin TTM 0%
Net Profit margin TTM 0%
Return on Investment TTM 0%
 Total Revenue  Net Income
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Sep 30, 2023
Total Revenue 319.41 353.61 295.57 315.75
Gross Profit 244.26 270.31 215.63 242.49
Operating Income 36.12 24.03 22.98 30.42
Net Income 11.46 3.28 9.19 4.77

000766 Balance Sheet

Quick Ratio MRQ 1.2
Current Ratio MRQ 1.92
LT Debt to Equity MRQ 66.51%
Total Debt to Equity MRQ 76.9%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Sep 30, 2023
Total Assets 4597.8 4599.57 4605.02 4466.27
Total Liabilities 2255.81 2269.09 2277.73 2148.43
Total Equity 2341.99 2330.48 2327.29 2317.83

000766 Cash Flow Statement

Cash Flow/Share TTM 0
Revenue/Share TTM -
Operating Cash Flow  11.61%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 73.3 49.31 -11.2 43.93
Cash From Investing Activities -9.31 -12.39 -4.45 -5.86
Cash From Financing Activities -52.03 -21.27 88.95 -86.17
Net Change in Cash 11.96 15.64 73.31 -48.1
* In Millions of CNY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

000766 Comments

Write your thoughts about Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email